MarketPulse

melanoma

5 articles
BenzingaBenzinga··Na

Galera and Obsidian Merge in All-Stock Deal, $350M Financing Fuels TIL Therapy Push

Galera and Obsidian merge in all-stock deal with $350M financing, creating Obsidian Therapeutics ($OBX) focused on TIL cell therapies with funding through 2028.
GRTXclinical trialsmerger agreement
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Cell Therapy Bet: $1B Revenue Dream Amid Manufacturing Headwinds

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.
IOVAbiotechoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion's Personalized Cancer Vaccine Shows 75% Response Rate in Extended Trial

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.
MRKEVAXphase 2 trialimmunotherapy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Personalized Cancer Therapy Targets 60%+ Growth, But Execution Risk Looms

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.
IOVAFDA approvalbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Iovance Biotherapeutics Expands Market Presence Following Amtagvi Approval

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.
IOVAbiotechclinical trials